Q3
– $15.1M Series B-1 financing
Q4
– Initiate Phase 1 study to evaluate RM-1929 in Recurrent HNSCC in Japan”
2018.04.02
Q3
– $15.1M Series B-1 financing
Q4
– Initiate Phase 1 study to evaluate RM-1929 in Recurrent HNSCC in Japan”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© Rakuten Medical Inc. 2022, All rights reserved.